BioSpace News Archive

Drug Development

Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo

Incyte announced new data from a Phase 2b clinical trial evaluating the safety and efficacy of povorcitinib, an investigational oral JAK1 inhibitor, in adult patients with extensive nonsegmental vitiligo.

March 18, 2023
·
9 min read
Policy

Public Advisory - Two lots of cystic fibrosis drug Cayston recalled due to the potential of cracked glass vials

Health Canada is advising the public that Gilead Sciences Incorporated recalled two lots of the cystic fibrosis drug Cayston on March 1, 2023, due to the potential of cracked glass vials in those lots, which may introduce glass particles into the medication.

March 18, 2023
·
2 min read
Drug Development

Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks

UCB, a global biopharmaceutical company, announced detailed positive results from two Phase 3 studies evaluating the efficacy and safety of bimekizumab in the treatment of adults with moderate to severe hidradenitis suppurativa.

March 18, 2023
·
14 min read
Biotech Beach

Connect Biopharma CBP-201 Atopic Dermatitis China Pivotal Study Showed Rapid Relief of Patient Symptoms

Connect Biopharma Holdings Limited announced that data from Stage 1 of the ongoing pivotal CBP-201 China trial in moderate-to-severe atopic dermatitis showed rapid relief from symptoms, as early as week one in some cases, and no efficacy plateau at Week 16.

March 18, 2023
·
5 min read
BioCapital

California Selects Civica Rx as Its Insulin Manufacturing Partner

Civica Inc. announced it will manufacture insulins for the State of California’s CalRx Biosimilar Insulin Initiative as part of its insulin manufacturing work.

March 18, 2023
·
5 min read
BioMidwest

Pivotal Clinical SAHARA Study Shows Candesant Biomedical’s Investigational Sweat Control Patch Significantly Reduces Primary Axillary Hyperhidrosis (Excessive Underarm Sweating)

Candesant Biomedical announced findings from its pivotal clinical study of its investigational sweat control patch, the first three-minute patch for the significant reduction of excessive underarm sweating in patients with primary axillary hyperhidrosis.

March 18, 2023
·
7 min read
BioMidwest

AbbVie Announces Late-Breaking Results of Study Evaluating 52-Week Efficacy and Safety of SKYRIZI® (risankizumab) in Plaque Psoriasis Patients With a Prior Suboptimal Response to IL-17 Inhibitor Therapy

AbbVie announced new 52-week data from an open-label, single-arm study demonstrating improved plaque psoriasis signs and symptoms among a difficult-to-treat patient population who received SKYRIZI®, an IL-23 inhibitor.

March 18, 2023
·
13 min read